Medical
NMPA Accepted Essex’s Biologics License Application for EB12-20145P (HLX04-O) for the Treatment of Wet Age-Related Macular Degeneration
Essex Bio-Technology Limited (Essex or the Group, HKG: 1061) is pleased to announce that a Biologics License Application (BLA) for EB12-20145P (HLX04-O), a recombinant...
Medical
Essex Bio-Technology Posts Sound 2023 Interim Financial Results, Revenue Up 37.1%, Profit Up 22%
Essex Bio-Technology Ltd (Essex or the Group, HKG: 1061) today announced the interim results for the six months ended 30 June 2023 (the period...
Medical
The phase 1/2 clinical trial of Bevacizumab for treatment of Ophthalmic Diseases completed
Essex Bio-Technology Ltd (Essex or the Group, HKG: 1061) today announced that a phase 1/2 clinical trial of EB12-20145P (HLX04-O), a recombinant anti-VEGF humanised...
Medical
Essex and Osteopore Entered into Exclusive Distribution Agreement for Oral Maxillofacial products in Singapore
Essex Bio-Technology Ltd. (Essex or the Group, HKG: 1061) is pleased to announce that its wholly-owned subsidiary, Majeton Pte. Ltd. (Majeton), has entered into...
Medical
Essex and Gunze Shenzhen Entered into Exclusive Agency Agreement for PELNAC Absorbable Dressing in Mainland China
Essex Bio-Technology Ltd. (Essex or the Group, HKG: 1061) is pleased to announce that its wholly-owned subsidiary, Essex Medipharma (Zhuhai) Co., Ltd. (Essex Medipharma),...
Medical
Essex Bio-Technology Announces 2022 Annual Financial Results
Resilience & Relevance, Growth Ready Essex Bio-Technology Ltd (Essex or the Group, HKG: 1061) today announced the annual results for the year ended 31...
Medical
Essex and Henlius signed amendment agreement for Global Co-Development and Exclusive License Agreement for treatment of age-related macular degeneration
Essex Bio-Technology Ltd (Essex or the Group, HKG: 1061) today announced that two of its wholly-owned subsidiaries, Essex Bio-Investment Limited (Essex Bio-Investment) and Zhuhai...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read
